$MCRB
Seres Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020033715 Filed on July 28, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $6.045M $7.620M $12.53M
YoY Change -51.76% -28.32% 171.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.490M $5.780M $5.570M
YoY Change 16.52% -23.24% -35.98%
% of Gross Profit
Research & Development $20.10M $21.03M $17.91M
YoY Change 12.25% -15.1% -25.56%
% of Gross Profit
Depreciation & Amortization $1.691M $1.800M $1.921M
YoY Change -11.97% -10.0% -1.69%
% of Gross Profit
Operating Expenses $26.59M $26.81M $23.48M
YoY Change 13.25% -16.98% -28.3%
Operating Profit -$20.55M -$19.19M -$10.95M
YoY Change 87.66% -11.44% -61.09%
Interest Expense -$650.0K -$210.0K $189.0K
YoY Change -443.92% -200.0% -45.85%
% of Operating Profit
Other Income/Expense, Net -$169.0K $630.0K $189.0K
YoY Change -189.42% 270.59% -45.85%
Pretax Income -$20.71M -$18.78M -$10.76M
YoY Change 92.47% -11.79% -61.28%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$20.71M -$18.78M -$10.76M
YoY Change 92.53% -11.79% -61.28%
Net Earnings / Revenue -342.66% -246.43% -85.86%
Basic Earnings Per Share
Diluted Earnings Per Share -$282.5K -$267.6K -$238.4K
COMMON SHARES
Basic Shares Outstanding 69.99M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.90M $94.82M $102.2M
YoY Change -37.48% 10.48% 6.35%
Cash & Equivalents $61.54M $65.13M $102.2M
Short-Term Investments $2.400M $29.69M
Other Short-Term Assets $5.800M $3.600M $5.200M
YoY Change 11.54% -47.06% -5.45%
Inventory
Prepaid Expenses
Receivables $2.929M $1.785M $1.604M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $72.72M $100.2M $109.0M
YoY Change -33.28% 8.12% 7.34%
LONG-TERM ASSETS
Property, Plant & Equipment $16.31M $19.50M $22.95M
YoY Change -28.94% -25.86% -23.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.400M $1.400M $1.500M
YoY Change -6.67% -6.67% 0.0%
Total Long-Term Assets $27.98M $32.25M $37.10M
YoY Change -24.57% 15.98% 18.09%
TOTAL ASSETS
Total Short-Term Assets $72.72M $100.2M $109.0M
Total Long-Term Assets $27.98M $32.25M $37.10M
Total Assets $100.7M $132.4M $146.1M
YoY Change -31.07% 9.93% 9.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.200M $4.859M $4.764M
YoY Change -11.84% -24.26% -7.64%
Accrued Expenses $8.200M $9.100M $8.000M
YoY Change 2.5% 82.0% 158.06%
Deferred Revenue $4.834M $2.689M
YoY Change -76.33% -85.03%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.20M $45.99M $43.07M
YoY Change 2.62% 9.4% 17.14%
LONG-TERM LIABILITIES
Long-Term Debt $24.90M $24.60M $0.00
YoY Change
Other Long-Term Liabilities $752.0K $502.0K $659.0K
YoY Change 14.11% -22.05% -41.63%
Total Long-Term Liabilities $752.0K $502.0K $659.0K
YoY Change 14.11% -22.05% -41.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.20M $45.99M $43.07M
Total Long-Term Liabilities $752.0K $502.0K $659.0K
Total Liabilities $166.3M $180.8M $164.1M
YoY Change 1.34% 7.27% 332.88%
SHAREHOLDERS EQUITY
Retained Earnings -$500.2M -$459.6M -$424.5M
YoY Change 17.85% 18.05% 22.63%
Common Stock $434.7M $411.3M $406.5M
YoY Change 6.93% 20.51% 22.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$65.58M -$48.32M -$17.97M
YoY Change
Total Liabilities & Shareholders Equity $100.7M $132.4M $146.1M
YoY Change -31.09% 9.93% 9.88%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$20.71M -$18.78M -$10.76M
YoY Change 92.53% -11.79% -61.28%
Depreciation, Depletion And Amortization $1.691M $1.800M $1.921M
YoY Change -11.97% -10.0% -1.69%
Cash From Operating Activities -$25.50M -$14.00M -$11.80M
YoY Change 116.1% -211.11% -53.91%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$200.0K -$300.0K
YoY Change -33.33% -200.0% -57.14%
Acquisitions
YoY Change
Other Investing Activities $17.90M $4.900M $0.00
YoY Change -71.51% -100.0%
Cash From Investing Activities $17.70M $4.700M -$300.0K
YoY Change -6000.0% -72.99% -100.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.60M 25.10M 60.70M
YoY Change -75.95% 25000.0% 60600.0%
NET CHANGE
Cash From Operating Activities -25.50M -14.00M -11.80M
Cash From Investing Activities 17.70M 4.700M -300.0K
Cash From Financing Activities 14.60M 25.10M 60.70M
Net Change In Cash 6.800M 15.80M 48.60M
YoY Change -86.01% -47.51% 345.87%
FREE CASH FLOW
Cash From Operating Activities -$25.50M -$14.00M -$11.80M
Capital Expenditures -$200.0K -$200.0K -$300.0K
Free Cash Flow -$25.30M -$13.80M -$11.50M
YoY Change 120.0% -211.29% -53.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2020Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45140830
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M24D
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16305000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10257000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4788000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75131834
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5186000
CY2020Q2 mcrb Revenue From Grant
RevenueFromGrant
831000
CY2020Q2 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
28000
CY2020Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
719000
CY2020Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
476000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-169000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
189000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10759000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
73306248
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10759000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29690000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
132440000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
24863000
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2826000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13181000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75131834
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70143252
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
411255000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-500244000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65575000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100678000
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
752000
CY2019Q2 mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
1817000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10648000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
434593000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-459649000
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2929000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
75000
CY2020Q2 us-gaap Liabilities
Liabilities
166253000
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10454000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
45993000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24648000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15676000
CY2019Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
89111000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3588000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4834000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4834000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
502000
CY2019Q4 us-gaap Liabilities
Liabilities
180764000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1785000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
72716000
us-gaap Interest Expense Debt
InterestExpenseDebt
1435000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
844000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-358000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
409000
mcrb Revenue From Grant
RevenueFromGrant
706000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17905000
mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
2016000
mcrb Revenue From Research Agreement
RevenueFromResearchAgreement
2077000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41842000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40792000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
70000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17069000
CY2019Q2 mcrb Revenue From Grant
RevenueFromGrant
260000
mcrb Revenue From Grant
RevenueFromGrant
1570000
CY2020Q2 us-gaap Revenues
Revenues
6045000
CY2019Q2 us-gaap Revenues
Revenues
12531000
us-gaap Revenues
Revenues
14234000
us-gaap Revenues
Revenues
19852000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20099000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6491000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5574000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12629000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13069000
us-gaap Restructuring Charges
RestructuringCharges
1492000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
26590000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
23479000
us-gaap Operating Expenses
OperatingExpenses
54471000
us-gaap Operating Expenses
OperatingExpenses
55353000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20545000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10948000
us-gaap Operating Income Loss
OperatingIncomeLoss
-40237000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35501000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
74000
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
189000
us-gaap Investment Income Interest
InvestmentIncomeInterest
233000
us-gaap Investment Income Interest
InvestmentIncomeInterest
409000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
us-gaap Net Income Loss
NetIncomeLoss
-35092000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.81
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
72063881
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43095686
us-gaap Net Income Loss
NetIncomeLoss
-40595000
us-gaap Net Income Loss
NetIncomeLoss
-35092000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70143252
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11837000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-700000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20703000
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10759000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40594000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35092000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-48045000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2019Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
153000
CY2019Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
207000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2065000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-24333000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-69833000
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60527000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2097000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10759000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-48324000
CY2020Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4178000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
120000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
249000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1959000
CY2020Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-10000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-19881000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-61649000
CY2020Q2 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
14848000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1914000
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
11000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-20714000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-65575000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
us-gaap Net Income Loss
NetIncomeLoss
-35092000
us-gaap Share Based Compensation
ShareBasedCompensation
3873000
us-gaap Share Based Compensation
ShareBasedCompensation
4162000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3493000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3927000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
1100000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
1097000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
102000
mcrb Noncash Interest Expense
NoncashInterestExpense
215000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1928000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1685000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1144000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1604000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11628000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-29000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-3004000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49817000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
299000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
647000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1645000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2163000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2079000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44181000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60759000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12931000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
40318000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27088000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-647000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
249000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
207000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
120000
mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
120000
mcrb Proceeds From Issuance Of Common Stock And Restricted Common Stock
ProceedsFromIssuanceOfCommonStockAndRestrictedCommonStock
153000
mcrb Proceeds From At The Market Equity Offering Net Of Commissions
ProceedsFromAtTheMarketEquityOfferingNetOfCommissions
18695000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19139000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61239000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3590000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
16411000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65126000
us-gaap Net Income Loss
NetIncomeLoss
-40595000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49817000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85933000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61536000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
102344000
us-gaap Interest Paid Net
InterestPaidNet
1226000
mcrb Unsettled Issuance Of Common Stock From At The Market Offering
UnsettledIssuanceOfCommonStockFromAtTheMarketOffering
331000
mcrb Issuance Costs From Public Offering Included In Accounts Payable And Accrued Payable
IssuanceCostsFromPublicOfferingIncludedInAccountsPayableAndAccruedPayable
232000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
66000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
88000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-500244000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
63940000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenue, operating expenses, clinical trials and employee-related amounts, will depend on future developments that are highly uncertain, including new information that may emerge concerning COVID-19 and the actions taken to contain it or treat its impact and the economic impact on local, regional, national and international markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results could differ from the Company’s estimates.</p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11618712
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8796896
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2019Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2019Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29690000
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2020Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1400000
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2403000
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2404000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29689000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47540000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
47237000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31235000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27742000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16305000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19495000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1691000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3493000
CY2019Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1921000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3927000
CY2020Q2 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
6263000
CY2019Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
5605000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3451000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4609000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
890000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
670000
CY2020Q2 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
10604000
CY2019Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
10884000
CY2019Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.30
us-gaap Restructuring Charges
RestructuringCharges
0
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
894000
us-gaap Payments For Restructuring
PaymentsForRestructuring
192000
CY2020Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
949000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
11970000
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
12081000
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
25000000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8310683
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.36
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3427000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4324865
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.52
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
141281
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
915785
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.91
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11578482
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.88
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10144000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4983417
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.91
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4670000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.34
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4162000
mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2020Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
5203000
CY2019Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
11526000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
11837000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
17069000
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-20-033715-index-headers.html Edgar Link pending
0001564590-20-033715-index.html Edgar Link pending
0001564590-20-033715.txt Edgar Link pending
0001564590-20-033715-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mcrb-10q_20200630.htm Edgar Link pending
mcrb-10q_20200630_htm.xml Edgar Link completed
mcrb-20200630.xsd Edgar Link pending
mcrb-20200630_cal.xml Edgar Link unprocessable
mcrb-20200630_def.xml Edgar Link unprocessable
mcrb-20200630_lab.xml Edgar Link unprocessable
mcrb-20200630_pre.xml Edgar Link unprocessable
mcrb-ex101_260.htm Edgar Link pending
mcrb-ex102_259.htm Edgar Link pending
mcrb-ex311_10.htm Edgar Link pending
mcrb-ex312_11.htm Edgar Link pending
mcrb-ex321_9.htm Edgar Link pending
mcrb-ex322_6.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending